我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 b! Q' j5 W+ r+ Author Affiliations

7 g6 _& a$ S; z8 d1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: N  F7 x5 t* K8 ?3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
' z2 }  E* \% V$ e, R- O5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
! |+ b- b- Y. _: ?; T8 w$ Y6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
! L1 C; x# M: m* `# s& X- O1 q% v2 o7Kinki University School of Medicine, Osaka 589-8511, Japan
+ {& E8 c9 p+ C' e8Izumi Municipal Hospital, Osaka 594-0071, Japan
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
" Z$ T+ h8 c& [, m6 r* @AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
3 v' ]' _  Q/ {: w# |9 L0 l* ]
) Q$ }: X7 t* v$ z' {# `0 ]

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
  I( Q* S5 k% e( s/ f
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
3 C) x( l% W; S* w1 a0 y
8 v8 Z- R! [% @1 W9 _Published online on: Thursday, December 1, 2011

Doi: 10.3892/ol.2011.507
& @; r5 ?- X4 k+ V4 e
Pages: 405-410

8 m5 \; s( R* x/ p7 |, n3 K6 A9 EAbstract:
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

* e* S* u6 z5 M# H

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
! I3 ~8 u8 s" i* P, u9 `: ~F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
: \+ l, B5 K4 i: z4 j+ Author Affiliations
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2Department of Thoracic Surgery, Kyoto University, Kyoto
7 Q6 v: c) B' A6 l# F! q. C3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
# k3 T* i8 Y8 f1 y$ vRevision received November 11, 2010.
( Y: }2 j. v* C5 xAccepted November 17, 2010.
Abstract
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
# t$ z5 r1 L1 C1 uPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
! Q: o2 ^4 }: V$ v; z; `" [

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
& e3 p) i( J: t- c  Xhttp://clinicaltrials.gov/ct2/show/NCT01523587
1 Y% r) {' H( t+ D" j7 H( u1 @0 Y' \
3 Z& O5 I3 q  Z6 U- RBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
: T+ y2 `& T; k$ n( _; @4 Zhttp://clinicaltrials.gov/ct2/show/NCT01156545

4 d* U9 W% J6 o, O. x从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出 ...

" H5 N% \7 @/ y5 Y8 ?- l没有副作用是第一追求，效果显著是第二追求。
0 T0 y0 }* C$ h不错。